MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood.2023019746

Медицинская библиотека · Blood · 2023

Natural history study of patients with familial platelet disorder with associated myeloid malignancy.

Cunningham Lea, Merguerian Matthew, Calvo Katherine R, Davis Joie, Deuitch Natalie T, Dulau-Florea Alina, Patel Nisha, Yu Kai, Sacco Keith, Bhattacharya Sumona, Passi Monica, Ozkaya Neval, De Leon Seila, Chong Shawn, Craft Kathleen, Diemer Jamie, Bresciani Erica, O'Brien Kevin, Andrews Elizabeth J, Park Nguyen, Hathaway Londa, Cowen Edward W, Heller Theo, Ryan Kerry, Barochia Amisha, Nghiem Khanh, Niemela Julie, Rosenzweig Sergio, Young David J, Frischmeyer-Guerrerio Pamela A, Braylan Raul, Liu Paul P

СтатьяПеревод в очереди

Аннотация

Deleterious germ line RUNX1 variants cause the autosomal dominant familial platelet disorder with associated myeloid malignancy (FPDMM), characterized by thrombocytopenia, platelet dysfunction, and a predisposition to hematologic malignancies (HMs). We launched a FPDMM natural history study and, from January 2019 to December 2021, enrolled 214 participants, including 111 patients with 39 different RUNX1 variants from 45 unrelated families. Seventy of 77 patients had thrombocytopenia, 18 of 18 had abnormal platelet aggregometry, 16 of 35 had decreased platelet dense granules, and 28 of 55 had abnormal bleeding scores. Nonmalignant bone marrows showed increased numbers of megakaryocytes in 12 of 55 patients, dysmegakaryopoiesis in 42 of 55, and reduced cellularity for age in 30 of 55 adult and 17 of 21 pediatric cases. Of 111 patients, 19 were diagnosed with HMs, including myelodysplastic syndrome, acute myeloid leukemia, chronic myelomonocytic leukemia, acute lymphoblastic leukemia, and smoldering myeloma. Of those 19, 18 were relapsed or refractory to upfront therapy and referred for stem cell transplantation. In addition, 28 of 45 families had at least 1 member with HM. Moreover, 42 of 45 patients had allergic symptoms, and 24 of 30 had gastrointestinal (GI) symptoms. Our results highlight the importance of a multidisciplinary approach, early malignancy detection, and wider awareness of inherited disorders. This actively accruing, longitudinal study will genotype and phenotype more patients with FPDMM, which may lead to a better understanding of the disease pathogenesis and clinical course, which may then inform preventive and therapeutic interventions. This trial was registered at www.clinicaltrials.gov as #NCT03854318.

Для цитирования: Cunningham Lea, Merguerian Matthew, Calvo Katherine R, Davis Joie, Deuitch Natalie T, Dulau-Florea Alina, Patel Nisha, Yu Kai, Sacco Keith, Bhattacharya Sumona, Passi Monica, Ozkaya Neval, De Leon Seila, Chong Shawn, Craft Kathleen, Diemer Jamie, Bresciani Erica, O'Brien Kevin, Andrews Elizabeth J, Park Nguyen, Hathaway Londa, Cowen Edward W, Heller Theo, Ryan Kerry, Barochia Amisha, Nghiem Khanh, Niemela Julie, Rosenzweig Sergio, Young David J, Frischmeyer-Guerrerio Pamela A, Braylan Raul, Liu Paul P. Natural history study of patients with familial platelet disorder with associated myeloid malignancy.. Blood. 2023. DOI: 10.1182/blood.2023019746.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.